Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from HBM Holdings Ltd. ( (HK:2142) ).
HBM Holdings Ltd. announced that the China National Intellectual Property Administration upheld its patent for a method of producing fully human heavy chain-only antibodies, following a challenge by Biocytogen Pharmaceuticals. This decision reinforces HBM’s intellectual property rights, allowing the company to continue leveraging its patented technology to develop innovative therapies, which could have significant implications for its market positioning and stakeholders.
More about HBM Holdings Ltd.
HBM Holdings Ltd. is a company incorporated in the Cayman Islands, focusing on the biotechnology industry. It specializes in the development of fully human heavy chain-only antibodies (HCAbs) using transgenic animals, aiming to advance transformative therapies in collaboration with global partners.
Average Trading Volume: 11,331,362
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.24B
See more data about 2142 stock on TipRanks’ Stock Analysis page.